Session Abstract – PMWC 2022 Silicon Valley


The COVID-19 pandemic is driving the unprecedented transformation of the global medical research ecosystem through the search for effective new therapeutics that can help ease symptoms and prevent death among COVID-19 patients.

  • SARS_CoV-2 Outbreak Surveillance (PANEL)
    Session Chair: Charles Chiu, UCSF
    - Bronwyn MacInnis, The Broad Institute - Duncan MacCannell, CDC
    - Ephraim Tsalik, Duke University
    - Joel Sevinsky, Theiagen
  • Experiences from the Front Lines of a National Viral Surveillance Organization
    Session Chair: James Lu, Helix
    - Rick Bright, Rockefeller Foundation
  • COVID-19 Testing: Who, When, What? The Challenges of Testing During the Pandemic
    Session Chair: Alan Wu, UCSF
    - Gary Pestano, Biodesix
    - John Barnes, CDC
    - Kathleen Jacobson, CA COVID Testing Task Force
  • Updates in COVID-19 Drug Development
    - Mark Dresser, Gilead Sciences
    - John Fahy, UCSF
    - Yi Shi, University of Pittsburgh
    - Wendy Yeh, Vir Biotechnology
  • Accelerating COVID-19 Therapeutic Interventions
    - Stacey Adam, FNIH
  • Past, Present, and Future: How will We Manage the Next Pandemic?
    Session Chair: Julianne McCall, California Initiative to Advance Precision Medicine
    - Lawrence Corey, Fred Hutchinson Cancer Research Center
    - Yvonne A Maldonado, Stanford
    - Robert Wachter, UCSF
    - Tomas Aragon, CDPH

 Session Chair Profile

M.D., Ph.D., Professor, Laboratory Medicine and Medicine/Infectious Diseases, UCSF

Biography
Charles Chiu, M.D./Ph.D. is a Professor at UCSF, Director of the UCSF-Abbott Viral Diagnostics and Discovery Center (VDDC), and Associate Director of the UCSF Clinical Microbiology Laboratory. Chiu currently leads a translational research laboratory focused on clinical metagenomic sequencing assay development for infectious diseases and genomic investigation and surveillance of emerging pathogens, including the SARS-CoV-2 coronavirus. He also uses RNA-Seq transcriptome profiling to develop predictive models using machine learning for host response-based diagnosis of COVID-19 and other infections. Chiu’s work is supported by funding from the National Institutes of Health (NIH), Department of Defense, US Centers for Disease Control and Prevention (CDC), philanthropy, and the California Initiative to Advance Precision Medicine. He has authored more than 100 peer-reviewed publications (>20 on COVID-19), holds over 15 patents and patent applications, and serves on the scientific advisory board for Mammoth Biosciences, Danaher Dx, Biomesense, and Flightpath.


 Session Chair Profile

M.D., Ph.D., Chief Executive Officer and Co-Founder, Helix

Biography
James is a co-founder and the Chief Executive Officer at Helix. Helix is the leading population genomics company operating at the intersection of clinical care, research, and genomics. Its end-to-end platform enables health systems, life sciences companies, and payers to advance genomic research and accelerate the integration of genomic data into clinical care. In response to the COVID-19 public health crisis, Helix launched a sensitive and scalable end-to-end COVID-19 test and viral surveillance system to meet the needs of health systems, employers, governments, and other organizations across the country. Prior to Helix, James was a faculty member at Duke University where he focused on translational genomics and machine learning methodologies for electronic medical records. James has also explored a broad range of research topics in population genetics, Mendelian genomics, and computational psychiatry and has published dozens of papers in journals such as Nature, the New England Journal of Medicine and the Journal of Machine Learning Research. Earlier in his career, James was a Lean Six Sigma Black Belt at Merck Pharmaceuticals, a global biopharma company, and an Associate at Devon Park Bioventures, a Philadelphia based healthcare venture capital firm. James holds an M.D. and Ph.D. from Baylor College of Medicine, where he was a member of the Alpha Omega Alpha Honor Society. He also received a B.S. and M.S. in Chemical Engineering from Stanford University.

Talk
Experiences from the Front Lines of a National Viral Surveillance Organization
Join us as we share the latest on respiratory variant trends. We'll discuss how healthcare organizations can leverage learnings to inform predictive analytics and provide real-world evidence, as we look beyond the pandemic and towards enabling healthier outcomes for communities now and into the future.


 Session Chair Profile

Ph.D., Professor, UCSF

Biography
Dr. Wu's research involves pharmacogenomics, cardiac biomarkers and clinical toxicology. With the onset of the COVID-19 pandemic, he has switch his focus towards molecular testing for the virus, antigen and antibodies after an infection and after a vaccine. Throughout his career, he has been a leader in promoting the value of clinical laboratory testing to the medical world, but especially the lay public. During the early months of the pandemic, the absence lab testing availability was directly linked to the spread of the virus.

Talk
Panel Discussion on COVID-19 Testing
COVID-19 Testing: Who, When, What? The Challenges of Testing during the Pandemic. In this panel, we will discuss how testing has evolved from the early months of the pandemic to the current unmet medical needs.


 Session Chair Profile

Ph.D., Co-Director of Precision Medicine, CA Governor's Office

Biography
Dr. McCall oversees cross-sector health policy working groups, research grantmaking, and public interagency efforts, which include serving on Governor Newsom's COVID-19 Testing Task Force and as co-author of the CA Surgeon General's Report. Previously, McCall worked at the California Senate Office of Research and as a Science and Technology Policy Fellow of the California Council on Science and Technology. Prior to state government, she spent sixteen years in neuroscience research labs, including as a Fulbright Fellow. In the community, Dr. McCall teaches Science Policy at UC Davis and UC Riverside, serves on the Editorial Board of the California Journal of Politics and Policy, occasionally directs the International Brain Bee, and is the co-founder of TEDxFulbright, the German Neuroscience Olympiad, and a chapter of the Sustained Dialogue Campus Network for racial justice. She earned a PhD from Heidelberg University, Master's degree from UC San Diego, and Bachelor's degree from Denison University.


 Speaker Profile

Ph.D., CSO, OAMD, Centers for Disease Control and Prevention

Biography
Duncan MacCannell is the chief science officer for the CDC’s Office of Advanced Molecular Detection (OAMD), where he helps coordinate the implementation and support of pathogen genomics, bioinformatics, high-performance computing and other innovative laboratory technologies across the CDC’s four infectious disease centers. With a broad focus on public health laboratory science and strategic innovation, he manages the agency's high performance computing center of excellence, and works to integrate standardized, sustainable capacity for advanced laboratory technologies and scientific computing into routine public health practice.


 Speaker Profile

M.D., M.H.S., Ph.D., Associate Professor, Division of Infectious Diseases, Duke Center for Applied Genomics & Precision Medicine, and the Department of Molecular Genetics & Microbiology, Duke University School of Medicine

Biography
Dr. Tsalik obtained his MD/PhD from Columbia University followed by residency in Internal Medicine and fellowship in Infectious Diseases at Duke University where he concurrently obtained a Masters of Health Science in Clinical Research. Dr. Tsalik’s research evaluates existing and emerging biomarkers, develops diagnostic platforms for pathogen identification and characterization, and has established a new paradigm for host response-based diagnostics. His research has been supported by DARPA, DTRA, VA, CDMRP/U.S. Army, and the NIH by way of the Antibacterial Resistance Leadership Group (ARLG) where Dr. Tsalik serves as the Associate Director of the ARLG Laboratory Center. His discoveries were the basis for the foundation of Predigen, a precision medicine diagnostics company. In 2021, Predigen merged with Biomeme, where Dr. Tsalik now serves as Chief Medical Officer. Biomeme’s vision is to empower anyone, anywhere with the knowledge to realize One Health.


 Speaker Profile

Ph.D., Director, Pathogen Genomic Surveillance, Broad Institute

Biography
Bronwyn MacInnis's primary focus is on developing and implementing genomic epidemiology and surveillance approaches for malaria and viral pathogens, and building local capacity to integrate these into routine public health and clinical practice. Bronwyn co-leads the Broad’s large scale COVID-19 genomic surveillance effort, working closely with the Massachusetts and other State Departments of Public Health and the US Centers for Disease Control to monitor variants of concern and to track the evolution and spread of SARS-CoV-2 in New England and beyond. She also co-leads the Broad’s multidisciplinary Global Health Initiative and is a visiting scientist at the Harvard T.H. Chan School of Public Health. Her global health focuses on malaria genomic surveillance, outbreak prevention and response, and genomics capacity building.


 Speaker Profile

Ph.D., Chief Scientific Officer, Q2 Solutions

Biography
Dr. Patrice Hugo is responsible for the medical affairs and scientific activities for the Central Laboratories, and Specialty Testing Centers of Excellence worldwide including the Expression Analysis Genomics, Vaccine, Biomarkers Translational Science and Innovation Laboratory and BioAnalytical/ADME laboratories. Prior to joining Q² Solutions, Dr. Hugo was Associate Vice President and Chief Clinical Trial Scientist at LabCorp/Covance Central Lab Division and Chief Scientific Officer at Clearstone Central Lab acquired by LabCorp. Previously, he worked at Caprion (now CellCarta) as Executive Vice President R&D, and Principal Investigator at the Montreal Clinical Research Institute with academic affiliation at McGill University and University of Montreal. Dr. Hugo obtained his Ph.D. in Experimental Medicine & Immunology at McGill University and held post-doctoral positions at the Walter and Eliza Hall Institute, Australia, and the Howard Hughes Medical Institute, USA. He is author or co-author of over 75 scientific manuscripts and has over 25 years of biomarker experience.


 Speaker Profile

Ph.D., Chief Development Officer; NYS CLEP Laboratory Director, Biodesix

Biography
Dr. Pestano is an experienced leader in Product Development and clinical Laboratory Operations. Prior to joining Biodesix, Dr. Pestano held senior positions in Pharma Services, R&D and Project Leadership at Ventana Medical Systems, a member of the Roche Group. Dr. Pestano’s experiences are specialized in high complexity molecular diagnostics for oncology and virology and include molecular, serologic, and proteomic testing. Dr. Pestano is the co-inventor on multiple national and international patents for diagnostic tests. He has also fostered many collaborations in academia, industry, quality, and public health consortia as a part of new product development. Dr. Pestano received his Ph.D. in Molecular Cell Biology at The Graduate Center, City University of New York where his thesis focused on vaccine development for novel genetic variants of HIV-1. He conducted his post-doctoral training in Cancer Immunology and AIDS at the Dana Farber Cancer Institute, Harvard Medical School.

Talk
Real World Testing in Support of bBack to Work Programs
Panelist providing real world perspective on multiple modalities of covid testing and studies in support of back to work programs.


 Speaker Profile

Ph.D., Senior Vice President, Gilead Sciences; President-Elect, ASCPT; Adjunct Professor, UCSF

Biography
Mark Dresser joined Gilead Sciences in 2020 as SVP, Biomarker Sciences and Clinical Pharmacology, where he oversees R&D efforts spanning biomarkers, diagnostics, clinical translational science, clinical pharmacology, pharmacometrics, and clinical bioanalysis. He has also served as Global Development Leader of Gilead’s 2nd Generation Remdesivir program. Mark was previously SVP and a founding member of the executive team at Denali Therapeutics, where he built numerous technical departments, including DMPK, Toxicology, and CMC. Under his leadership, Denali advanced five compounds into clinical development, and Mark also played a key role in the company’s successful IPO in 2017. He previously held scientific leadership positions at Genentech and Johnson & Johnson. In 2019, Mark received the UCSF Graduate Division Alumnus of the Year Award for his contributions to science and medicine. He completed his education and training at UCSF, Rensselaer Polytechnic Institute and the Swiss Federal Institute of Technology.


 Speaker Profile

M.D., Professor / Principal Investigator, Fred Hutchinson Cancer Research Center

Biography
Dr. Larry Corey is an internationally renowned expert in virology, immunology and vaccine development, and the former president and director of the Fred Hutchinson Cancer Research Center. His research focuses on herpes viruses, HIV, the novel coronavirus and other viral infections, including those associated with cancer. He is principal investigator of the HIV Vaccine Trials Network, or HVTN, which conducts studies of HIV vaccines at over 80 clinical trials sites in 16 countries on five continents. Dr. Corey is also the principal investigator of the Fred Hutch-based operations center of the COVID-19 Prevention Network (CoVPN) and co-leads the Network’s COVID-19 vaccine testing pipeline. The CoVPN is carrying out the large Operation Warp Speed portfolio of COVID-19 vaccines and monoclonal antibodies intended to protect people from COVID-19.


 Speaker Profile

M.D., Professor of Medicine, UCSF

Biography
John Fahy directs the UCSF Severe Asthma Faculty Practice and the UCSF Airway Clinical Research Center. His NIH supported research program aims to uncover disease mechanisms and to develop disease biomarkers and novel treatments for airway disease. His program is truly translational, encompassing clinical trials and investigations in patients and studies of disease mechanisms in cell culture and animal model systems. In clinical studies his lab aims to provide a molecular understanding of the clinical heterogeneity of airway disease and to explore new treatment options. In bench laboratory studies his lab focuses on how pathologic mucus forms in the airway in acute and chronic airway disease, on development of mucolytic drugs, and on mechanisms of persistent type 2 inflammation in asthma. In therapeutics he has specific interest and expertise in thiol drugs and he has applied this expertise to studies of thiol drugs as therapeutics for COVID19.

Talk
Thiol Drugs to Treat COVID19
Thiol drugs have anti-oxidant and anti-inflammatory properties that could limit SARS-CoV-2 lung injury or alter the redox status of the SARS-CoV-2 spike to disrupt ACE2 binding. We screened thiol drugs to show that they can act as virus entry inhibitors in vitro and modifiers of lung injury in hamsters.


 Speaker Profile

Ph.D., Assistant Professor, University of Pittsburgh

Biography
My research has been focused on developing cutting-edge mass spec/proteomics technologies and protein bioengineering. Recently, we developed a robust proteomics pipeline to revolutionize nanobody (Nb)-drug discovery, and identified a large repertoire (> 8,000) of high-affinity, multi-epitope Nbs that target SARS-CoV-2 glycoprotein. Critically, we have demonstrated the outstanding preclinical efficacy of a stable, ultrapotent Nb for novel inhalation therapy of SARS-CoV-2 infection in a sensitive COVID-19 disease model. High-resolution cryoEM determination of Nb-bound structures reveals multiple potent neutralizing epitopes that target cryptic and conserved sites. Comparisons of neutralizing antibodies and Nbs provide insights into how Nbs target the spike to achieve high-affinity and broad activity. Structure-function analysis of Nbs indicates a variety of antiviral mechanisms. Our technologies will find broad utility in other devastating diseases including infectious diseases and cancer

Talk
Inhalation COVID Therapy by Ultrapotent Nanobodies


 Speaker Profile

M.D., Senior Associate Dean for Faculty Development and Diversity; Professor of Pediatrics and of Epidemiology and Population Health; Chief, Division of Pediatric Infectious Diseases, Stanford University School of Medicine

Biography
Dr. Maldonado is a pediatric infectious diseases epidemiologist. She attended Stanford University School of Medicine, completed pediatric residency and pediatric infectious diseases fellowship at Johns Hopkins University, and was an Epidemic Intelligence Service Officer at the Centers for Disease Control and Prevention before joining the faculty at Stanford University. She has led a number of NIH, CDC, Gates Foundation and WHO funded domestic and international pediatric infectious diseases studies, focused on pediatric HIV and pediatric vaccine preventable diseases. More recently, she has focused on health disparities and infectious diseases outcomes, including COVID-19 in pediatric and adult populations. She is chair of the American Academy of Pediatrics Committee on Infectious Diseases and a liaison to the CDC Advisory Committee on Immunization Practices. She has over 230 peer reviewed publications and is co-editor of the textbook “Infectious Diseases of the Fetus and Newborn Infant” and the American Academy of Pediatrics “Red Book”.


 Speaker Profile

Ph.D., Associate Vice President. FNIH

Biography
Stacey plays a leadership role at the FNIH, helping to lead many public-private partnerships, such as Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) the PPP that evaluated hundreds of available therapeutic agents with potential application for COVID-19, prioritized them, and designed and launched multiple master protocols to test them. Stacey oversees the Cancer, Metabolic Diseases and Clinical COVID Research portfolios at the Foundation for the National Institute of Health (FNIH). Beyond ACTIV other major partnerships under her guidance include the two steering committees of the Biomarkers Consortium and their projects, Partnership for Accelerating Cancer Therapies (PACT), and the Lung Master protocol (Lung-MAP) clinical trial. Prior to FNIH, she was a Manager at Deloitte Consulting within the Federal Life Sciences and Healthcare Strategy. She received her PhD at Duke and postdoctoral training at Stanford.


 Speaker Profile

M.D., Professor and Chair, Department of Medicine, UCSF

Biography
Robert M. Wachter, MD is Professor and Chair of the Department of Medicine at the University of California, San Francisco. He coined the term “hospitalist” in 1996 and is often considered the “father” of the hospitalist field, the fastest growing medical specialty in U.S. history. His 2015 book, The Digital Doctor: Hope, Hype and Harm at the Dawn of Medicine’s Computer Age, was a New York Times science bestseller. Thirteen times, Modern Healthcare magazine has ranked him as one of the 50 most influential physician-executives in the U.S.; he was #1 on the list in 2015. In 2020-21, his tweets on Covid-19 served as a trusted source of information on the clinical, public health, and policy issues surrounding the pandemic.


 Speaker Profile

Ph.D., CEO, Theiagen Genomics

Biography
Dr. Sevinsky has leveraged over two decades of experience in systems biology and taken aim at transforming public health and infectious disease surveillance through innovative implementation of NGS and bioinformatics technologies. During a three year tenure at the Colorado Department of Public Health and Environment, he led several initiatives to build NGS testing and bioinformatics capacity at the state, regional and national levels. In 2019 Dr. Sevinsky’s ambitions to impact public health exceeded his role as a government scientist, resulting in the formation of Theiagen Genomics. Dr. Sevinsky and his team now work with over four dozen public health laboratories nationally, and more than a dozen internationally in Africa and Asia. Prior to his time in public health, Dr. Sevinsky held several positions in non-profit and industry, working in applied technologies for diverse applications such as biomarker identification and biofuel/biochemical production.


 Speaker Profile

M.D., Dr. P.H., Director and State Public Health Officer, California Department of Public Health

Biography
Dr. Tomás Aragón serves as the director of the California Department of Public Health and the State Public Health Officer, since January 4, 2021. Prior to coming to CDPH, he was the health officer for the City and County of San Francisco and director of the public health division. Dr. Aragón has served in public health leadership roles for more than 20 years (communicable disease controller, deputy health officer, health officer, community health and chronic disease epidemiologist), including directing a public health emergency preparedness and response research and training center at the University of California, Berkeley School of Public Health. As CDPH director, striving to embody and promote the universal values of dignity, equity, compassion and humility, he works through collaborative partnerships to mobilize communities and institutions to transform policies and systems towards a culture of equity, antiracism, healing and health for all people and our planet. As State Public Health Officer, he exercises leadership and legal authority to protect health and prevent disease. Dr. Aragón graduated from University of California, Berkeley (B.A., Molecular Biology; Dr.P.H., Epidemiology), Harvard Medical School (M.D.), Harvard School of Public Health (M.P.H.), and Stanford University (certification in Strategic Decision and Risk Management in Healthcare). He completed his clinical and research training at University of California, San Francisco (San Francisco General Hospital Primary Care Internal Medicine; Clinical Infectious Diseases; and Traineeship in AIDS Prevention Studies).​


 Speaker Profile

Ph.D., Team lead- CDC influenza Division Genomics and Diagnostics Team, CDC

Biography
Internationally recognized expert in the field of influenza viral genomics and diagnostics. Responsible for Manufacturing and Maintaining 6 FDA approved diagnostic assays including CDC’s Influenza A/B SARS-CoV-2 Multiplex Assay. Sequenced and published first RNA genome by sequencing the viral RNA directly. Team is one of the largest producers of influenza genomic data in the world.


 Speaker Profile

M.D., President, Mayo Clinic Platform

Biography
Dr. John D. Halamka, M.D., M.S., is an American business executive and physician. He is president of the Mayo Clinic Platform, a group of digital and long-distance health care initiatives. Trained in emergency medicine and medical informatics, Halamka has been developing and implementing health care information strategy and policy for more than 25 years. He specializes in artificial intelligence, the adoption of electronic health records and the secure sharing of healthcare data for care coordination, population health, and quality improvement. In 2020, Halamka was elected to the National Academy of Medicine (NAM). Prior to his appointment at Mayo Clinic, he was chief information officer at Beth Israel Deaconess Medical Center. He is a practicing emergency medicine physician. As the International Healthcare Innovation Professor at Harvard Medical School, Halamka helped the George W. Bush administration, the Obama administration and governments around the world plan their health care information strategies.

Talk
The Breadth and Depth of Trustless Data Sharing Technology
This session brings together two sides of the data sharing innovation landscape – technologists and traditional healthcare systems. The group will discuss the breadth and depth of the impact data sharing technologies will have for insurers, digital health companies, and traditional healthcare systems seeking to innovate and push precision medicine forward.